EUCTR2009-015877-11-DE进行中（未招募）不适用
An Observer-Blinded, Randomized Study Comparing the Safety and Immunogenicity of HEPLISAV™ to Licensed Vaccine (Engerix-B®) among Adults (18 to 75 Years of Age) with Chronic Kidney Disease (CKD) - Immunogenicity and Safety of HEPLISAV™ Hepatitis B Virus Vaccine in Chronic Kidney Disease Patients
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A subject must meet all of the following inclusion criteria to participate in the study:
- •1. be 18 to 75 years of age;
- •2. has loss of renal function as defined by a GFR = 45 mL/min/1.73 m2;
- •3. be clinically stable in the opinion of the investigator;
- •4. be serum negative for HBsAg, anti-HBsAg, anti-HBcAg, HCV, and HIV;
- •5. if a woman of childbearing potential, agree to consistently use a highly effective method of birth control from screening visit through the treatment phase and for up to 28 days after the last injection;
- •6. is not scheduled to undergo a kidney transplant in the next 12 months;
- •7. be able and willing to provide informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 282
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 237
排除标准
- •A subject who meets any 1 of the following exclusion criteria is not permitted to participate in the study:
- •1. if female, is pregnant, breastfeeding, or planning a pregnancy;
- •2. has a history of or is considered by the investigator to be at high risk for recent exposure to HBV, HCV, or HIV; for example, current intravenous drug use, unprotected sex with known HBV/HIV positive partner;
- •3. has known history of autoimmune disease;
- •4. has previously received any hepatitis B vaccine;
- •5. has a history of sensitivity to any component of study vaccines;
- •6. has current illness other than renal disease or has substance or alcohol abuse that, in the opinion of the investigator, would interfere with compliance or with interpretation of the study results;
- •7. is undergoing chemotherapy or expected to receive chemotherapy during the study period; has a diagnosis of cancer within the last 5 years other than squamous or basal cell carcinoma of the skin;
- •8. has uncontrolled diabetes or hypertension;
- •9. is unwilling or unable to comply with all the requirements of the protocol;
- •10. has received any blood products or immunoglobulin within 3 months prior to study entry, or likely to require infusion of blood products during the study period;
- •11. has received the following prior to the first injection:
- •3 days: erythropoietin (exclusionary window does not apply for subjects on dialysis)
- •7 days: intravenous iron
- •21 days: any inactivated virus vaccine
- •– any live virus vaccine
- •– systemic corticosteroids (more than 3 consecutive days) or other immunomodulators or immune suppressive medication, with the exception of inhaled steroids
- •– granulocyte or granulocyte-macrophage colony-stimulating factor (G/GM-CSF)
- •– any other investigational medicinal agent
- •At any time: an injection of DNA plasmids or oligonucleotides.
研究者
相似试验
招募中
2 期
Clinical trial on detergent powder in healthy human volunteersCTRI/2023/12/060978ILEVER INDUSTRIES PRIVATE LIMITED
招募中
3 期
Skin irritancy potential of detergents in healthy human volunteersCTRI/2024/04/065908nilever Industries Private Limited
已完成
3 期
Clinical trial on detergents in healthy human volunteersCTRI/2023/07/055614nilever Industries Private Limited24
尚未招募
不适用
comparison of two different treatment methods for migraine headache not relived by usual medical treatment.CTRI/2018/08/015208Post graduation institute of medical education and research
尚未招募
Unknown
Comparision Of Intravenous Lignocaine VS Ondansetron For Prevention OF Post Operative Nausea Vomiting In Laparoscopic Surgeries.CTRI/2023/10/058834Rajarajeswari Medical College And Hospital